Etoricoxib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Etoricoxib: From NSAID Pain Relief to Migraine Disorder
One-Sentence Summary
Etoricoxib is a selective COX-2 inhibitor (NSAID class); the evidence pack does not contain a confirmed original UK-approved indication text. The TxGNN model predicts it may be effective for Migraine Disorder, but this is currently supported by 0 clinical trials and 0 publications — the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in this evidence pack (data gap — DG002); Etoricoxib is pharmacologically a selective COX-2 inhibitor NSAID |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 (model prediction only, no clinical/literature support) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (data gap DG002). Based on general pharmacological knowledge, etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor within the NSAID class, and its anti-inflammatory/analgesic efficacy in musculoskeletal and acute pain conditions is well established in the literature outside this dataset.
The proposed mechanistic link for migraine is that COX-2 and downstream prostaglandin signalling are theorised to play a role in the neuroinflammatory and vasodilatory components of migraine pathophysiology. However, the evidence pack itself states plainly that this rationale is theoretical: no etoricoxib-specific trial or publication was retrieved for “migraine disorder,” “migraine with brainstem aura,” or the related susceptibility phenotype. The 20 publications returned for the “susceptibility” variant are genetic/epileptogenesis background studies (e.g., SCN1A, MTHFR C677T polymorphisms) and do not test etoricoxib or any COX-2 inhibitor therapeutically.
By contrast, the pack does contain genuine (if limited) supportive signal for a related but distinct indication — “headache disorder” (rank 9) — where case reports and a case series describe etoricoxib benefiting indomethacin-responsive headache syndromes (idiopathic stabbing headache, secondary cough headache) via COX-2 inhibition sparing COX-1-mediated GI toxicity relative to indomethacin. This is a more mechanistically grounded and evidence-backed hypothesis than the top-ranked “migraine disorder” prediction, and is flagged separately below.
Clinical Trial Evidence
Currently no related clinical trials registered for Migraine Disorder.
Literature Evidence
Currently no related literature available for Migraine Disorder.
UK Market Information
Etoricoxib currently holds no UK marketing authorisation in this evidence pack (0 licenses; market status: not marketed). Where marketed internationally, etoricoxib is classified under NSAIDs, COX-2 selective inhibitors (BNF-equivalent chapter 10.1.1); this classification is provided for context only and is not confirmed against a UK-specific licence in this dataset.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications and DDI data were all flagged as data gaps in this evidence pack (DG001, Blocking severity — TFDA/MHRA label warnings and contraindications not yet retrieved). This must be resolved before any safety-dependent decision (S1 stage) can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked prediction (Migraine Disorder, TxGNN score 99.90%) has no supporting clinical trials or literature — it is evidence level L5, decision stage S0. A blocking data gap also exists for label-level safety information (DG001), which by itself prevents progression to safety screening (S1).
To proceed, the following is needed:
- TFDA/MHRA label warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action data from DrugBank (DG002, High)
- Dedicated clinical or observational data testing etoricoxib specifically in migraine (none currently exist)
- Confirmation of UK marketing/licensing status, since etoricoxib is not currently marketed in this dataset
Other Predicted Indications Considered (For Context)
Of the ten candidates in this evidence pack, only two carry any real supporting evidence — both stronger than the top-ranked migraine prediction:
| Disease | TxGNN Score | Evidence Level | Decision Stage | Recommendation | Basis |
|---|---|---|---|---|---|
| Headache disorder | 99.31% | L4 | S1 | Research Question | 3 case reports + 1 case series describing etoricoxib benefit in indomethacin-responsive headache syndromes (idiopathic stabbing headache, secondary cough headache); PMIDs 35277974, 36893522, 17883876, 18171381 |
| Trigeminal autonomic cephalalgia | 99.15% | L5 | S0 | Hold | No direct evidence; mechanistically adjacent to the headache-disorder signal above (shared indomethacin-responsive subtype rationale) |
Pulmonary hypertension (rank 6) and kyphoscoliotic heart disease (rank 8) also returned trial/literature hits, but all describe COX-2 inhibition as a risk factor (sodium/water retention, hyperkalaemia) rather than a therapeutic mechanism, and should not be interpreted as supportive evidence.
If this candidate is pursued further, headache disorder — not migraine disorder — is the better-evidenced starting point for a research question at S1.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.